Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (41-50 of 157) with videos related to

Pageof 16
Sort By:
Antiviral Therapy|June 28, 2016
Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studiesEric Lawitz, Fred Poordad, Robert H Hyland, et al.
Hepatology (Baltimore, Md.)|August 20, 2010
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis CFred Poordad, Eric Lawitz, Mitchell L Shiffman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2012
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infectionElliot B Tapper, Eric B Cohen, Keyur Patel, et al.
Nature Communications|November 6, 2023
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitisPhilip N Newsome, Arun J Sanyal, Guy Neff, et al.
European Journal of Clinical Pharmacology|October 21, 2018
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairmentMatthew P Kosloski, Haoyu Wang, David Pugatch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2019
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported OutcomesZobair M Younossi, Maria Stepanova, Ira Jacobson, et al.
Antiviral Therapy|October 25, 2017
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitorEric Lawitz, Jenny C Yang, Luisa M Stamm, et al.
Antiviral Therapy|December 14, 2011
Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patientsKeyur Patel, Seng G Lim, Chow W Cheng, et al.
Leukemia & Lymphoma|June 9, 2016
Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment<sup/>Jan de Jong, Donna Skee, Peter Hellemans, et al.
Virology Journal|January 31, 2018
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infectionFabien Zoulim, Christophe Moreno, Samuel S Lee, et al.
Pageof 16

Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
Antiviral Therapy|June 28, 2016
Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studiesEric Lawitz, Fred Poordad, Robert H Hyland, et al.
Hepatology (Baltimore, Md.)|August 20, 2010
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis CFred Poordad, Eric Lawitz, Mitchell L Shiffman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2012
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infectionElliot B Tapper, Eric B Cohen, Keyur Patel, et al.
Nature Communications|November 6, 2023
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitisPhilip N Newsome, Arun J Sanyal, Guy Neff, et al.
European Journal of Clinical Pharmacology|October 21, 2018
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairmentMatthew P Kosloski, Haoyu Wang, David Pugatch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2019
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported OutcomesZobair M Younossi, Maria Stepanova, Ira Jacobson, et al.
Antiviral Therapy|October 25, 2017
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitorEric Lawitz, Jenny C Yang, Luisa M Stamm, et al.
Antiviral Therapy|December 14, 2011
Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patientsKeyur Patel, Seng G Lim, Chow W Cheng, et al.
Leukemia & Lymphoma|June 9, 2016
Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment<sup/>Jan de Jong, Donna Skee, Peter Hellemans, et al.
Virology Journal|January 31, 2018
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infectionFabien Zoulim, Christophe Moreno, Samuel S Lee, et al.
Pageof 16